Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 7/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24494651 | 1.00 | HCAR3 (0.37) | HCAR3NAMPTNPC1MAPTGRM2 | |
| SCHEMBL6733449 | 0.87 | HCAR3 (0.39) | HCAR3NAMPTNPC1MAPTGRM2 | |
| SCHEMBL3782203 | 0.84 | DGAT1 (0.42) | HCAR3NPC1DGAT1MEN1RAB9A | |
| SCHEMBL31666996 | 0.83 | POLB (0.41) | HCAR3NAMPTNPC1MAPTMEN1 | |
| SCHEMBL2144514 | 0.82 | NPC1 (0.40) | HCAR3NAMPTNPC1MAPTDGAT1 | |
| SCHEMBL30991716 | 0.82 | SLC9A1 (0.39) | HCAR3NPC1GRM2SLC9A1PTK2 | |
| SCHEMBL23619038 | 0.82 | HCAR3 (0.38) | HCAR3NAMPTNPC1DGAT1MEN1 | |
| SCHEMBL19023657 | 0.82 | SLC9A1 (0.39) | HCAR3NPC1GRM2SLC9A1PTK2 | |
| SCHEMBL6729750 | 0.79 | HCAR3 (0.39) | HCAR3NAMPTNPC1MAPTDGAT1 | |
| SCHEMBL38655160 | 0.79 | HCAR3 (0.36) | HCAR3NAMPTNPC1GRM2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
| WO-2022116998-A1 | FUSED HETEROCYCLIC DERIVATIVES AS HBV INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | HCAR3 879/4885NAMPT 1/4885NPC1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.